Haemonetics (NYSE: HAE) reported Q4 EPS of $0.77, $0.07 better than the analyst estimate of $0.70. Revenue for the quarter came in at $304 million versus the consensus estimate of $290.79 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.